Reply to Letter to the Editor: "Can ARNI Prevent Doxorubicin-Induced Cardiotoxicity?"

Abstract

We thank the authors for reading with great interest. In our study, as in previous studies, semi-quantitative histological analysis was performed.1 It was stated that the limitations of our study were that imaging methods, especially invasive methods and hemodynamic measurements, were not used. Doxorubicin (DOX)-induced cardiotoxicity can occur in acute and chronic periods. It is known in the literature that left ventricular systolic dysfunction accompanies DOX-induced ventricular-related acute arrhythmogenic events.2,3 In a recent study, it was found that natriuretic peptide levels predicted late-stage cardiotoxicity due to DOX.4 In our study, the ability of electrocardiography and natriuretic peptide data to predict both acute and chronic cardiotoxicities due to DOX has been already proven in clinical studies in the literature.